Aortic valve prosthesis

titanium

A revolutionary medical device in the field of cardiology, significantly improving the quality of life of patients with degenerative or congenital valve disease. Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria: A device lifespan at least equal to that of the patient, to avoid the need for a second surgical procedure. This means more than 30 million flap openings and closures per year, with no leaks, blockages, cracks, ruptures or flap escapes. The artificial valve must not lead to thrombosis, so that patients do not need to take anticoagulants. Operation (flap opening and closing, blood flow through the valve) must be as silent as possible, so as not to disturb the patient or those around him, day or night. Characteristics* Lifespan at least equal to that of patients Superior hemodynamics to current mechanical valves Total biocompatibility with blood thanks to the use of implantable medical-grade materials Low thrombogenicity Remarkably silent Easily implantable Designed for patients of all ages The TRIFLO valve offers many advantages over mechanical and biological artificial valves on the market. From the outset of Novostia's development, MPS has been guided by the fundamental requirements determined by the functioning of a human heart.